<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796428</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-2019-00002051</org_study_id>
    <nct_id>NCT04796428</nct_id>
  </id_info>
  <brief_title>GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial</brief_title>
  <acronym>GOLDEN-AGE</acronym>
  <official_title>Intraclass Safety and Efficacy Comparison Among SGLT-2 Inhibitors in Elderly Patients With Type 2 Diabetes. A Pragmatic, Phase IV, Multicenter, Open-label, Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Outcomes Research and Clinical Epidemiology, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Society of Diabetology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Outcomes Research and Clinical Epidemiology, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three SGLT2i were commercially available in Italy at the time the trial was designed:&#xD;
      canagliflozin, dapagliflozin, and empagliflozin. Preliminary evidence suggests that the&#xD;
      higher dose canagliflozin (300 mg/day) might exert a stronger glucose-lowering effect than&#xD;
      dapagliflozin or empagliflozin. The clinical relevance of this putative difference is however&#xD;
      unknown. On the other side, the use of canagliflozin, but not empagliflozin and&#xD;
      dapagliflozin, has been associated with an increased risk of some adverse events, namely bone&#xD;
      fractures and lower limb amputations. Currently, the available information on the efficacy&#xD;
      and safety of SGLT2i in elderly (70+ years) patients with type 2 diabetes are is very scant.&#xD;
      Thus, a compelling need now exists of comparing efficacy and safety of the commercially&#xD;
      available SGLT2i in a population of frail patients at high risk of cardiovascular and renal&#xD;
      diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The primary objective is to compare the proportion of patients treated with each SGLT2i drug, who achieve the individualized HbA1c target without level-2 hypoglycaemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - HbA1c</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in HbA1c level (as a continuous variable) - %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - body weight</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in body weight (as a continuous variable) - Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - systolic blood pressure</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in systolic blood pressure (as a continuous variable) - mmHG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - e-GFR</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in e-GFR (as a continuous variable). The slope of eGFR decline will be calculated over time in the three treated groups - mL/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - urinary albumin excretion rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in urinary albumin excretion rate (as a continuous variable) - mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - medications</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change concomitant medications and their daily dosages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - treatment satisfaction</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Change in treatment satisfaction quantified as Diabetes Treatment Satisfaction Questionnaire (DTSQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives - biomarkers</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Plasma/serum biomarkers of bone metabolism and cardiac function (in a subset of patients) with physiological parameter</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Hospitalization for any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Hospitalization for heart failure and/or cardiovascular causes</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All-cause death and Cardiovascular death</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Severe hypoglycemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Genitourinary tract infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Dehydration / hypovolemia events</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Bone fractures</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Leg/foot amputations</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Objectives</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Diabetic ketoacidosis</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1167</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>canagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg (or 50/850 mg and 50/1000 mg of the fixed association with metformin) or 300 mg (or the 150/850 mg and the 150/1000 mg fixed association with metformin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 10/5 mg of the fixed dapagliflozin / saxagliptin combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 5/5 mg of the empagliflozin / linagliptin combination) or 25 mg (or the 12.5/850 mg and the 12.5/1000 mg fixed association with metformin; or the 12.5/5 mg empagliflozin / linagliptin combination).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.</description>
    <arm_group_label>canagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.&#xD;
If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used.</description>
    <arm_group_label>dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.&#xD;
If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used.</description>
    <arm_group_label>empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Age 70+ years&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Prevalent cardiovascular disease (symptomatic or asymptomatic) or eGFR &lt;90 ml/min/1.73&#xD;
             m2 and above the lower limit for initiation of SGLT2i according to label (currently&#xD;
             eGFR &lt;60 ml/min/1.73 m2)&#xD;
&#xD;
          -  HbA1c above individualized target&#xD;
&#xD;
          -  Indication to add SGLT2i&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;90 years&#xD;
&#xD;
          -  Estimated life expectancy &lt;1 year&#xD;
&#xD;
          -  Very high risk of genitourinary tract infections (&gt;2 events in the last 6 months)&#xD;
&#xD;
          -  Recent weight loss (&gt;5% in &lt;6 months)&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

